CONDENSED CONSOLIDATED STATEMENTS OF CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS' EQUITY (UNAUDITED) - USD ($) $ in Thousands	Convertible Preferred Stock Series A-1 convertible preferred stock	Convertible Preferred Stock	Common Stock Common stock Public offering	Common Stock Common stock Stock Purchase Agreement	Common Stock Common stock	Common Stock Class A common stock	Additional Paid-In Capital Series A-1 convertible preferred stock	Additional Paid-In Capital Public offering	Additional Paid-In Capital Stock Purchase Agreement	Additional Paid-In Capital	Accumulated Other Comprehensive Loss	Accumulated Deficit	Series A-1 convertible preferred stock	Public offering	Stock Purchase Agreement	Total
Balance at the beginning of the period at Dec. 31, 2020		$ 0			$ 3	$ 0				$ 309,288	$ (6,067)	$ (147,101)				$ 156,123
Balance at the beginning of the period (in shares) at Dec. 31, 2020		2,978			25,948,712	3,819,732
Increase (Decrease) in Stockholders' Equity
Issuance of common stock upon exercise of stock options					$ 0					125						125
Issuance of common stock upon exercise of stock options (in shares)					33,806
Vesting of restricted stock					$ 0					0
Vesting of restricted stock (in shares)					12,140
Foreign currency translation adjustment, net of tax											(476)					(476)
Stock-based compensation expense										1,521						1,521
Net loss												(17,238)				(17,238)
Balance at the end of the period at Mar. 31, 2021		$ 0			$ 3	$ 0				310,934	(6,543)	(164,339)				140,055
Balance at the end of the period (in shares) at Mar. 31, 2021		2,978			25,994,658	3,819,732
Balance at the beginning of the period at Dec. 31, 2020		$ 0			$ 3	$ 0				309,288	(6,067)	(147,101)				156,123
Balance at the beginning of the period (in shares) at Dec. 31, 2020		2,978			25,948,712	3,819,732
Increase (Decrease) in Stockholders' Equity
Foreign currency translation adjustment, net of tax																288
Net loss																(54,430)
Balance at the end of the period at Sep. 30, 2021		$ 0			$ 3	$ 0				315,394	(5,779)	(201,532)				108,086
Balance at the end of the period (in shares) at Sep. 30, 2021		2,978			26,084,065	3,819,732
Balance at the beginning of the period at Dec. 31, 2020		$ 0			$ 3	$ 0				309,288	(6,067)	(147,101)				156,123
Balance at the beginning of the period (in shares) at Dec. 31, 2020		2,978			25,948,712	3,819,732
Increase (Decrease) in Stockholders' Equity
Net loss																(75,700)
Balance at the end of the period at Dec. 31, 2021		$ 0			$ 3	$ 0				317,135	(4,780)	(222,766)				89,592
Balance at the end of the period (in shares) at Dec. 31, 2021		1,697			27,383,483	3,819,732
Balance at the beginning of the period at Mar. 31, 2021		$ 0			$ 3	$ 0				310,934	(6,543)	(164,339)				140,055
Balance at the beginning of the period (in shares) at Mar. 31, 2021		2,978			25,994,658	3,819,732
Increase (Decrease) in Stockholders' Equity
Issuance of common stock upon exercise of stock options					$ 0					112						112
Issuance of common stock upon exercise of stock options (in shares)					45,681
Vesting of restricted stock					$ 0					0
Vesting of restricted stock (in shares)					11,507
Foreign currency translation adjustment, net of tax											293					293
Stock-based compensation expense										2,627						2,627
Net loss												(17,153)				(17,153)
Balance at the end of the period at Jun. 30, 2021		$ 0			$ 3	$ 0				313,673	(6,250)	(181,492)				125,934
Balance at the end of the period (in shares) at Jun. 30, 2021		2,978			26,051,846	3,819,732
Increase (Decrease) in Stockholders' Equity
Issuance of common stock upon exercise of stock options					$ 0					2						2
Issuance of common stock upon exercise of stock options (in shares)					21,912
Vesting of restricted stock					$ 0					0
Vesting of restricted stock (in shares)					10,307
Foreign currency translation adjustment, net of tax											471					471
Stock-based compensation expense										1,719						1,719
Net loss												(20,040)				(20,040)
Balance at the end of the period at Sep. 30, 2021		$ 0			$ 3	$ 0				315,394	(5,779)	(201,532)				108,086
Balance at the end of the period (in shares) at Sep. 30, 2021		2,978			26,084,065	3,819,732
Balance at the beginning of the period at Dec. 31, 2021		$ 0			$ 3	$ 0				317,135	(4,780)	(222,766)				89,592
Balance at the beginning of the period (in shares) at Dec. 31, 2021		1,697			27,383,483	3,819,732
Increase (Decrease) in Stockholders' Equity
Issuance of stock	$ 0		$ 2	$ 0			$ 29,625	$ 40,685	$ 5,000				$ 29,625	$ 40,687	$ 5,000
Issuance of stock (in shares)	15,800		21,700,000	1,666,666
Issuance of common stock upon exercise of stock options					$ 0					1						1
Issuance of common stock upon exercise of stock options (in shares)					10,034
Vesting of equity grants					$ 0					0
Vesting of equity grants (in shares)					112,551
ATM costs										(142)						(142)
Foreign currency translation adjustment, net of tax											(487)					(487)
Stock-based compensation expense										1,621						1,621
Net loss												(17,968)				(17,968)
Balance at the end of the period at Mar. 31, 2022		$ 0			$ 5	$ 0				393,925	(5,267)	(240,734)				147,929
Balance at the end of the period (in shares) at Mar. 31, 2022		17,497			50,872,734	3,819,732
Balance at the beginning of the period at Dec. 31, 2021		$ 0			$ 3	$ 0				317,135	(4,780)	(222,766)				$ 89,592
Balance at the beginning of the period (in shares) at Dec. 31, 2021		1,697			27,383,483	3,819,732
Increase (Decrease) in Stockholders' Equity
Issuance of common stock upon exercise of stock options (in shares)																34,223
Foreign currency translation adjustment, net of tax																$ (2,855)
Net loss																(52,604)
Balance at the end of the period at Sep. 30, 2022		$ 0			$ 5	$ 0				396,348	(7,635)	(275,370)				113,348
Balance at the end of the period (in shares) at Sep. 30, 2022		17,497			52,317,138	2,399,517
Balance at the beginning of the period at Mar. 31, 2022		$ 0			$ 5	$ 0				393,925	(5,267)	(240,734)				147,929
Balance at the beginning of the period (in shares) at Mar. 31, 2022		17,497			50,872,734	3,819,732
Increase (Decrease) in Stockholders' Equity
Issuance of common stock upon exercise of stock options					$ 0					1						1
Issuance of common stock upon exercise of stock options (in shares)					12,062
Foreign currency translation adjustment, net of tax											(1,001)					(1,001)
Stock-based compensation expense										1,381						1,381
Net loss												(16,356)				(16,356)
Balance at the end of the period at Jun. 30, 2022		$ 0			$ 5	$ 0				395,307	(6,268)	(257,090)				131,954
Balance at the end of the period (in shares) at Jun. 30, 2022		17,497			50,884,796	3,819,732
Increase (Decrease) in Stockholders' Equity
Conversion of Class A common stock to common stock					$ 0	$ 0
Conversion of Class A common stock to common stock (in shares)					1,420,215	(1,420,215)
Issuance of common stock upon exercise of stock options					$ 0					1						1
Issuance of common stock upon exercise of stock options (in shares)					12,127
Foreign currency translation adjustment, net of tax											(1,367)					(1,367)
Stock-based compensation expense										1,040						1,040
Net loss												(18,280)				(18,280)
Balance at the end of the period at Sep. 30, 2022		$ 0			$ 5	$ 0				$ 396,348	$ (7,635)	$ (275,370)				$ 113,348
Balance at the end of the period (in shares) at Sep. 30, 2022		17,497			52,317,138	2,399,517